Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest tumor Stories

2014-02-14 08:26:33

Clinical and Regulatory Plans for Two Lead Products Announced SAN DIEGO, Feb. 14, 2014 /PRNewswire/ -- MultiVir, a leader in gene therapies for cancer treatment, presented to the investment community at the Leerink Global Healthcare Conference. Highlights of the presentation included an overview of the development plans for the company's two lead products which are supported by strong pre-clinical and clinical data. MultiVir's adenoviral p53 (Ad-p53) and adenoviral interleukin 24...

2014-02-11 08:32:18

US and Japanese patents cover the Company's whole slide imaging and analysis platform, which simultaneously measures tumor, immune, and stromal cells, processes, and biomarkers on a single specimen PITTSBURGH, Feb. 11, 2014 /PRNewswire/ -- Cernostics, a diagnostics company delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that the United States Patent and Trademark Office has issued two patents, US Patent 8,114,615 and US Patent...

2014-02-04 11:57:02

Largest-ever study of 20-year survival among pediatric low-grade glioma patients highlights radiation's association with higher mortality The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults. However, children who received radiation as part of their treatment had significantly lower long-term...

2014-02-04 11:02:59

Presence of IDH1 mutation determines best treatment for malignant astrocytomas Astrocytomas are the most common malignant brain tumors. While most patients' tumors prove to be quite aggressive, outcomes overall can vary widely, with some patients surviving for many years. Now a new study has found that malignant astrocytoma patients whose tumors carry a specific genetic mutation benefit greatly from surgical removal of the largest possible amount of tumor. Preliminary results of the study...

2014-01-30 23:22:28

This report from BCC Research focuses on circulating tumor cell testing and monitoring methods, and includes an overview on cancer, diagnostic strategies, and treatment technologies. Important trends in the field of cancer research and development are reviewed and sales forecasts by treatment and screening categories are provided from 2013 through 2018. Wellesley, MA (PRWEB) January 30, 2014 According to a new technical market research report Circulating Tumor Cell (CTC) Diagnostics:...

2014-01-30 12:28:48

International studies demonstrate importance of comprehensive tumor profiling for poor-prognosis cancer patients IRVING, Texas, Jan. 30, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present two tumor profiling studies at the 2014 Genitourinary Cancers Symposium held this week in San Francisco, Calif. Through use of the company's comprehensive tumor profiling service, Caris Molecular Intelligence,...

2014-01-29 08:29:12

Studies address technical sensitivity, specificity, pharmacodynamics, heterogeneity and patient selection relevant to prostate cancer patient management SAN DIEGO and SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ -- Epic Sciences, in collaboration with the company's academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical College, University of Michigan, and Progenics Pharmaceuticals, will present six novel...

2014-01-29 08:29:11

Agreement provides important access point to meet global demand for Epic's technology SAN DIEGO, Jan. 29, 2014 /PRNewswire/ -- Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials. For Epic's clinical trial partners and customers, LabCorp's Central Laboratory in Mechelen, Belgium is able to quickly...

2014-01-28 23:03:54

An early stage study shows melatonin – a hormone that regulates the body’s sleep and awake cycles – may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo. Detroit, Michigan (PRWEB) January 28, 2014 An early stage study shows melatonin – a hormone that regulates the body’s sleep and awake cycles – may have the potential to...

Melatonin Therapy May Help Slow Breast Cancer Tumor Growth
2014-01-28 14:19:25

Brett Smith for redOrbit.com - Your Universe Online Produced by the brain in response to darkness and often taken as a sleep aid supplement, melatonin could be effective in slowing the growth of certain breast cancer tumors, according to a new report published in the open-access journal PLOS ONE. More specifically, melatonin may stunt tumor growth and tumor cell production, as well as obstruct the generation of new blood vessels in breast cancer cells that test negative for estrogen...